Abbott Laboratories (ABL.F)
| Previous Close | 94.73 |
| Open | 94.50 |
| Bid | 93.86 x 90000 |
| Ask | 94.82 x 90000 |
| Day's Range | 94.41 - 95.36 |
| 52 Week Range | 85.41 - 111.18 |
| Volume | |
| Avg. Volume | 174 |
| Market Cap | 166.135B |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | 32.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.03 (2.15%) |
| Ex-Dividend Date | Apr 12, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.
- PR Newswire
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
- ACCESSWIRE
It's Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...
